Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
36.66
-0.65 (-1.74%)
At close: Jan 17, 2025, 4:00 PM
36.65
-0.01 (-0.03%)
After-hours: Jan 17, 2025, 4:00 PM EST
Guardant Health Revenue
Guardant Health had revenue of $191.48M in the quarter ending September 30, 2024, with 33.87% growth. This brings the company's revenue in the last twelve months to $692.26M, up 29.20% year-over-year. In the year 2023, Guardant Health had annual revenue of $563.95M with 25.45% growth.
Revenue (ttm)
$692.26M
Revenue Growth
+29.20%
P/S Ratio
6.43
Revenue / Employee
$389,126
Employees
1,779
Market Cap
4.53B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
GH News
- 4 days ago - Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development - Business Wire
- 6 days ago - Viz.ai to Collaborate With Guardant Health to Improve Lung Cancer Detection, Diagnosis, and Treatment - Business Wire
- 7 days ago - Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results - Business Wire
- 13 days ago - Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute's Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection - Business Wire
- 18 days ago - Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care - Business Wire
- 4 weeks ago - COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics - Business Wire
- 4 weeks ago - Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer - Business Wire